State-of-the-art strategies for targeting the DNA damage response in cancer

State-of-the-art strategies for targeting the DNA damage response in cancerState-of-the-art strategies for targeting the DNA damage response in cancer, Published online: 24 October 2018; doi:10.1038/s41571-018-0114-zInhibition of poly(ADP-ribose) polymerase (PARP) is the paradigmatic example of synthetic lethal therapy and is predicated on exploiting DNA repair deficiencies that are a hallmark of cancer. In this Review, the authors review the progress made to date with PARP inhibitors and describe the expanding landscape of novel anticancer therapies targeting the DNA damage response. Potential predictive biomarkers, mechanisms of resistance and combinatorial strategies are discussed.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research